Geron Corporation (0IV3.L)
USD 3.93
(-1.38%)
USD 3.93
(-1.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -193.94 Million USD | -39.98% |
| 2022 | -138.55 Million USD | -21.54% |
| 2021 | -113.99 Million USD | -48.22% |
| 2020 | -76.91 Million USD | -6.08% |
| 2019 | -72.5 Million USD | -133.34% |
| 2018 | -31.07 Million USD | -6.21% |
| 2017 | -29.25 Million USD | 4.54% |
| 2016 | -30.64 Million USD | -5382.29% |
| 2015 | -559 Thousand USD | 98.46% |
| 2014 | -36.31 Million USD | 6.79% |
| 2013 | -38.95 Million USD | 45.71% |
| 2012 | -71.75 Million USD | 25.34% |
| 2011 | -96.11 Million USD | 13.54% |
| 2010 | -111.16 Million USD | -58.28% |
| 2009 | -70.23 Million USD | -4.76% |
| 2008 | -67.04 Million USD | -6.69% |
| 2007 | -62.83 Million USD | -32.68% |
| 2006 | -47.36 Million USD | -25.59% |
| 2005 | -37.71 Million USD | 53.61% |
| 2004 | -81.28 Million USD | -169.33% |
| 2003 | -30.18 Million USD | 15.46% |
| 2002 | -35.7 Million USD | -1.94% |
| 2001 | -35.01 Million USD | -33.6% |
| 2000 | -26.21 Million USD | -26.02% |
| 1999 | -20.8 Million USD | -65.08% |
| 1998 | -12.6 Million USD | -15.6% |
| 1997 | -10.9 Million USD | 10.66% |
| 1996 | -12.2 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -69.33 Million USD | -23.51% |
| 2024 Q1 | -56.13 Million USD | -3.4% |
| 2023 Q3 | -47.61 Million USD | 8.35% |
| 2023 Q1 | -40.09 Million USD | 4.43% |
| 2023 Q4 | -54.28 Million USD | -14.02% |
| 2023 Q2 | -51.95 Million USD | -29.58% |
| 2023 FY | -193.94 Million USD | -39.98% |
| 2022 FY | -138.55 Million USD | -21.54% |
| 2022 Q1 | -28.67 Million USD | 7.45% |
| 2022 Q2 | -27.97 Million USD | 2.44% |
| 2022 Q3 | -39.94 Million USD | -42.79% |
| 2022 Q4 | -41.95 Million USD | -5.01% |
| 2021 Q2 | -28.88 Million USD | -1.53% |
| 2021 Q1 | -28.45 Million USD | -22.3% |
| 2021 Q3 | -25.67 Million USD | 11.13% |
| 2021 FY | -113.99 Million USD | -48.22% |
| 2021 Q4 | -30.98 Million USD | -20.67% |
| 2020 Q3 | -20.01 Million USD | -19.41% |
| 2020 Q1 | -16.87 Million USD | 43.78% |
| 2020 FY | -76.91 Million USD | -6.08% |
| 2020 Q2 | -16.76 Million USD | 0.64% |
| 2020 Q4 | -23.26 Million USD | -16.24% |
| 2019 Q3 | -15.97 Million USD | -4.91% |
| 2019 FY | -72.5 Million USD | -133.34% |
| 2019 Q1 | -11.3 Million USD | -17.85% |
| 2019 Q2 | -15.22 Million USD | -34.71% |
| 2019 Q4 | -30 Million USD | -87.88% |
| 2018 Q1 | -7.43 Million USD | 4.48% |
| 2018 Q2 | -7.24 Million USD | 2.62% |
| 2018 Q3 | -6.8 Million USD | 6.03% |
| 2018 Q4 | -9.58 Million USD | -40.91% |
| 2018 FY | -31.07 Million USD | -6.21% |
| 2017 FY | -29.25 Million USD | 4.54% |
| 2017 Q1 | -7.49 Million USD | 14.66% |
| 2017 Q3 | -7.24 Million USD | -7.62% |
| 2017 Q2 | -6.73 Million USD | 10.18% |
| 2017 Q4 | -7.78 Million USD | -7.48% |
| 2016 Q3 | -3.87 Million USD | 56.49% |
| 2016 Q1 | -9.07 Million USD | -5.01% |
| 2016 Q4 | -8.78 Million USD | -126.49% |
| 2016 FY | -30.64 Million USD | -5382.29% |
| 2016 Q2 | -8.91 Million USD | 1.83% |
| 2015 Q1 | -9.45 Million USD | -4.94% |
| 2015 FY | -559 Thousand USD | 98.46% |
| 2015 Q3 | 27.02 Million USD | 385.05% |
| 2015 Q2 | -9.47 Million USD | -0.24% |
| 2015 Q4 | -8.64 Million USD | -131.99% |
| 2014 FY | -36.31 Million USD | 6.79% |
| 2014 Q4 | -9.01 Million USD | 9.04% |
| 2014 Q3 | -9.9 Million USD | -14.36% |
| 2014 Q1 | -8.73 Million USD | 5.87% |
| 2014 Q2 | -8.66 Million USD | 0.78% |
| 2013 Q2 | -8.96 Million USD | 25.2% |
| 2013 Q1 | -11.98 Million USD | 35.16% |
| 2013 FY | -38.95 Million USD | 45.71% |
| 2013 Q4 | -9.27 Million USD | -6.21% |
| 2013 Q3 | -8.73 Million USD | 2.59% |
| 2012 Q2 | -18.47 Million USD | 2.32% |
| 2012 Q3 | -15.87 Million USD | 14.08% |
| 2012 Q4 | -18.48 Million USD | -16.42% |
| 2012 FY | -71.75 Million USD | 25.34% |
| 2012 Q1 | -18.91 Million USD | 37.79% |
| 2011 Q2 | -21.41 Million USD | 12.07% |
| 2011 FY | -96.11 Million USD | 13.54% |
| 2011 Q4 | -30.4 Million USD | -52.53% |
| 2011 Q1 | -24.35 Million USD | 59.14% |
| 2011 Q3 | -19.93 Million USD | 6.91% |
| 2010 Q1 | -16.47 Million USD | 10.31% |
| 2010 FY | -111.16 Million USD | -58.28% |
| 2010 Q4 | -59.61 Million USD | -227.48% |
| 2010 Q3 | -18.2 Million USD | -7.86% |
| 2010 Q2 | -16.87 Million USD | -2.42% |
| 2009 Q4 | -18.37 Million USD | -12.02% |
| 2009 Q2 | -18.75 Million USD | -12.28% |
| 2009 Q1 | -16.7 Million USD | 26.42% |
| 2009 FY | -70.23 Million USD | -4.76% |
| 2009 Q3 | -16.4 Million USD | 12.57% |
| 2008 Q4 | -22.7 Million USD | -26.59% |
| 2008 Q2 | -15.45 Million USD | 3.08% |
| 2008 FY | -67.04 Million USD | -6.69% |
| 2008 Q3 | -17.93 Million USD | -16.02% |
| 2008 Q1 | -15.94 Million USD | -11.25% |
| 2007 Q2 | -16.76 Million USD | -2.22% |
| 2007 Q4 | -14.33 Million USD | 6.51% |
| 2007 FY | -62.83 Million USD | -32.68% |
| 2007 Q1 | -16.4 Million USD | -26.21% |
| 2007 Q3 | -15.33 Million USD | 8.54% |
| 2006 Q4 | -12.99 Million USD | -7.46% |
| 2006 FY | -47.36 Million USD | -25.59% |
| 2006 Q3 | -12.09 Million USD | -6.01% |
| 2006 Q2 | -11.4 Million USD | -5.03% |
| 2006 Q1 | -10.86 Million USD | -3.16% |
| 2005 Q2 | -3.89 Million USD | 62.4% |
| 2005 Q4 | -10.52 Million USD | 18.51% |
| 2005 FY | -37.71 Million USD | 53.61% |
| 2005 Q1 | -10.36 Million USD | -7.6% |
| 2005 Q3 | -12.92 Million USD | -231.56% |
| 2004 Q2 | -9.16 Million USD | 82.37% |
| 2004 Q3 | -10.47 Million USD | -14.26% |
| 2004 Q1 | -52.01 Million USD | -530.74% |
| 2004 FY | -81.28 Million USD | -169.33% |
| 2004 Q4 | -9.63 Million USD | 8.06% |
| 2003 Q3 | -5.23 Million USD | 39.48% |
| 2003 Q1 | -8.04 Million USD | -5.34% |
| 2003 Q2 | -8.65 Million USD | -7.57% |
| 2003 Q4 | -8.24 Million USD | -57.46% |
| 2003 FY | -30.18 Million USD | 15.46% |
| 2002 Q2 | -9.48 Million USD | 14.78% |
| 2002 Q3 | -7.44 Million USD | 21.56% |
| 2002 Q4 | -7.63 Million USD | -2.61% |
| 2002 Q1 | -11.13 Million USD | -34.4% |
| 2002 FY | -35.7 Million USD | -1.94% |
| 2001 Q2 | -7.42 Million USD | 15.96% |
| 2001 FY | -35.01 Million USD | -33.6% |
| 2001 Q4 | -8.28 Million USD | 20.98% |
| 2001 Q3 | -10.48 Million USD | -41.27% |
| 2001 Q1 | -8.83 Million USD | -103.41% |
| 2000 Q1 | -7.07 Million USD | -33.49% |
| 2000 Q4 | -4.34 Million USD | 31.57% |
| 2000 Q3 | -6.34 Million USD | 3.34% |
| 2000 FY | -26.21 Million USD | -26.02% |
| 2000 Q2 | -6.56 Million USD | 7.24% |
| 1999 Q3 | -6.9 Million USD | -50.0% |
| 1999 Q2 | -4.6 Million USD | -21.05% |
| 1999 FY | -20.8 Million USD | -65.08% |
| 1999 Q1 | -3.8 Million USD | 0.0% |
| 1999 Q4 | -5.3 Million USD | 23.19% |
| 1998 Q3 | -3.3 Million USD | 0.0% |
| 1998 Q4 | -3.8 Million USD | -15.15% |
| 1998 Q2 | -3.3 Million USD | -50.0% |
| 1998 Q1 | -2.2 Million USD | -29.41% |
| 1998 FY | -12.6 Million USD | -15.6% |
| 1997 Q1 | -4.6 Million USD | -21.05% |
| 1997 Q4 | -1.7 Million USD | 26.09% |
| 1997 FY | -10.9 Million USD | 10.66% |
| 1997 Q3 | -2.3 Million USD | 0.0% |
| 1997 Q2 | -2.3 Million USD | 50.0% |
| 1996 Q2 | -2.7 Million USD | -3.85% |
| 1996 FY | -12.2 Million USD | 0.0% |
| 1996 Q4 | -3.8 Million USD | -22.58% |
| 1996 Q3 | -3.1 Million USD | -14.81% |
| 1996 Q1 | -2.6 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -14.637% |
| Dynavax Technologies Corporation | -37.02 Million USD | -423.777% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -3580.85% |
| Perrigo Company plc | 151.9 Million USD | 227.679% |
| Illumina, Inc. | -1.06 Billion USD | 81.857% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 102.828% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 57.889% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.622% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 109.81% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -75.332% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 104.792% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -334.2% |
| Waters Corporation | 817.67 Million USD | 123.719% |
| Biogen Inc. | 1.29 Billion USD | 114.956% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 29.219% |
| Evolus, Inc. | -49.23 Million USD | -293.931% |
| Adicet Bio, Inc. | -152.03 Million USD | -27.563% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -59.631% |
| bluebird bio, Inc. | -244.26 Million USD | 20.6% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -24.672% |
| FibroGen, Inc. | -281.81 Million USD | 31.18% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 114.366% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -330.248% |
| Homology Medicines, Inc. | -48.25 Million USD | -301.915% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 31.268% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -163.891% |
| Myriad Genetics, Inc. | -123.7 Million USD | -56.786% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -92.353% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 62.362% |
| Zoetis Inc. | 3.06 Billion USD | 106.319% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -302.373% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 117.837% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 199.744% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 104.502% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -395.349% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 45.172% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 29.732% |
| Verastem, Inc. | -92.08 Million USD | -110.616% |
| Nektar Therapeutics | -137.42 Million USD | -41.127% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 16.34% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -99.209% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 27.585% |
| OPKO Health, Inc. | -157.02 Million USD | -23.515% |
| Exelixis, Inc. | 170.88 Million USD | 213.494% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 177.299% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 280.78% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -247.844% |
| uniQure N.V. | -282.87 Million USD | 31.437% |
| Imunon, Inc. | -21.03 Million USD | -822.207% |
| Blueprint Medicines Corporation | -486.27 Million USD | 60.117% |
| Insmed Incorporated | -709.62 Million USD | 72.67% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 157.452% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 50.46% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1039.97% |
| Incyte Corporation | 620.52 Million USD | 131.255% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 73.301% |